Skip to main content
. 2024 Jul 26;13(7):3783–3797. doi: 10.21037/tcr-24-747

Figure 3.

Figure 3

Network graphs of eligible trials assessing tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia for nine outcomes. (A) MMR 3; (B) MMR 6; (C) MMR 12; (D) CCyR 6; (E) CCyR 12; (F) all grades adverse events; (G) anemia of grade 3 or 4; (H) thrombocytopenia of grade 3 or 4; (I) neutropenia of grade 3 or 4; (J) ALT elevation of all grades; (K) AST elevation of all grades. MMR, major molecular response; CCyR, complete cytogenic response; ALT, alanine aminotransferase; AST, aspartate aminotransferase; IM, imatinib; DAS, dasatinib; NIL, nilotinib; BOS, bosutinib; RAD, radotinib; FLU, flumatinib; QD, quaque die; BID, bis in die.